Health Topics — Neurological
Eye Pressure, Glaucoma, and Four Decades of Cannabinoid Research
One of the oldest observations in cannabinoid science — a plain account of what the research has found, and why it has not translated into treatment.
The connection between cannabis and eye pressure is one of the oldest observations in cannabinoid research — noted in the 1970s, studied repeatedly since, and still generating more questions than it has answered. If you have glaucoma or elevated eye pressure and you have heard that cannabis helps, you have heard something that is partly true and significantly more complicated than it sounds.
This is the plain account of what the research has actually found over forty years — and why the finding has not translated into clinical treatment.
Glaucoma is a group of eye conditions in which damage to the optic nerve — usually associated with elevated intraocular pressure — causes progressive vision loss. Intraocular pressure (IOP) is the pressure of the fluid inside the eye. When drainage of that fluid is impaired, pressure builds and damages the optic nerve over time. Managing IOP — lowering it and keeping it low — is the primary strategy for slowing glaucoma progression.
The cannabinoid finding that has attracted attention for forty years is straightforward: cannabis reduces intraocular pressure. This was documented in the 1970s and has been replicated in multiple forms since. The endocannabinoid system is present in the eye's fluid-regulating structures — the ciliary body and trabecular meshwork — and CB1 receptors there modulate aqueous humor production and outflow, the processes that govern IOP. The biology is sound. The finding is real.
Why the finding hasn't become a treatment
The IOP reduction produced by cannabinoids lasts approximately three to four hours. Glaucoma is a chronic, progressive condition that requires sustained IOP control, typically around the clock. To manage IOP with cannabinoids, a patient would need to dose every three to four hours — including through the night — producing a constant state of cannabinoid activity in the body. This is not a practical treatment regimen, and the systemic effects of that frequency of dosing are not acceptable.
The IOP-lowering effect is primarily attributed to THC — the psychoactive compound in cannabis — acting on CB1 receptors in the eye. CBD, and CBG, do not appear to produce the same direct IOP-lowering effect. In fact, some research has found that CBD may partially counteract the IOP-lowering effect of THC in some contexts. This is a significant distinction for anyone considering hemp-derived preparations, which contain no significant THC.
CBG has been studied in the glaucoma context specifically — animal model research has found that CBG produces some IOP reduction through its own CB1 activity in ocular tissue. The CBG finding is real and is why CBG research in glaucoma exists. But the same duration problem applies: the effect is short-lived, and no human trial has established CBG as a viable glaucoma treatment.
What this means for someone with glaucoma
Glaucoma has highly effective conventional treatments — eye drops that reduce IOP with once or twice daily dosing, laser procedures, and surgery for refractory cases. The cannabinoid finding, while scientifically interesting, has not improved on these treatments in terms of efficacy, duration, practicality, or side effect profile. The American Academy of Ophthalmology does not recommend cannabis for glaucoma treatment, and for good reason: the available treatments are more effective and more practical.
If you have glaucoma, the most important thing this article can offer is the honest framing: the cannabinoid-IOP finding is real, but it does not support using hemp-derived cannabinoid preparations to manage glaucoma. The compounds most relevant to the IOP-lowering effect — particularly THC — are not present in hemp preparations. And even with THC, the practical obstacles to sustained IOP management are significant.
On glaucoma and clinical care
Glaucoma is a serious eye condition managed by ophthalmologists. Untreated or poorly managed elevated IOP causes permanent, irreversible vision loss. Any changes to glaucoma management — including the addition of any supplement or preparation — should be discussed with your ophthalmologist.
The research section contains the full mechanism article on glaucoma and cannabinoids — with the complete IOP research history, CBG's specific ocular findings, and the neuroprotective optic nerve research that represents a different and potentially more relevant direction for cannabinoid glaucoma research.
The cannabis-IOP finding is one of the most replicated observations in cannabinoid research — and one of the most misrepresented. The research is real. The practical obstacles to using it as a glaucoma treatment are also real. We have tried to present both accurately, because the person with glaucoma deserves a clear account of what forty years of research has and hasn't established.
These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.